Yi (Lily) Li

Sixty Degree Capital thesis

Headqaurters: San Francisco, CA, USA Subsector: MedTech Everside Health Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Everside Health’s Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Everside Health’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administra

Sector and stage focus

• Series B: BioTech, Health & Hospital Services, Digital Health, Health IT
• Seed: BioTech, Health IT, Digital Health, Health & Hospital Services
• Series A: Health IT, BioTech, Health & Hospital Services, Digital Health
• general: British Columbia

Is Yi (Lily) Li a fit for your round?

Upload your pitch deck and see whether Yi (Lily) Li appears in your top 20 matches.